AbbVie Reports Strong Phase 3 Results for Myeloma Treatment Etentamig
On September 3, AbbVie (ABBV) announced positive results from its Phase 3 CERVINO trial of etentamig in relapsed or refractory multiple myeloma. The drug achieved a 74% objective response rate compared to 45.7% for standard therapy and reduced the risk of disease progression by 60%. Etentamig also demonstrated improved safety, with lower rates of infections and cytokine release syndrome than current BCMA bispecifics like Tecvayli (Johnson & Johnson), Elrexfio (Pfizer), or Lynozyfic (Regeneron). The drug is expected to be filed for regulatory approval in 2026. AbbVie's CEO emphasized the potential of etentamig as a treatment that can be administered outside academic centers, expanding its market reach. In parallel, AbbVie acquired Apogee Therapeutics and reported positive Phase 3 results for atogepant in menstrual migraine on September 10, reinforcing management’s long-term growth strategy beyond immunology. The company's Q2 2026 financials showed revenue of $16.99 billion with adjusted EPS beating estimates. With a strong gross margin and return on invested capital, AbbVie is positioned to capitalize on its oncology pipeline while maintaining solid performance in immunology.
Tickers: $ABBV $JNJ $PFE $REGN
Topics: AbbVie BCMA-directed T-cell engager etentamig multiple myeloma Phase 3 trial